Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
37
Participants
Timeline
Start Date
October 10, 2025
Primary Completion Date
October 31, 2026
Study Completion Date
October 31, 2028
Conditions
Advanced Ovarian Cancer
Interventions
DRUG
Senaparib
100mg qd
DRUG
Bevacizumab
7.5mg/kg q3w
Trial Locations (1)
200032
Fudan University Shanghai Cancer Center, Shanghai
All Listed Sponsors
lead
Fudan University
OTHER
NCT07120451 - Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker | Biotech Hunter | Biotech Hunter